# Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer

_Oncology Research · Xiaojing Liu, Beibei Hua, Yang Xia et al. · 2026_

Canonical: https://diginpl.com/books/paper-or-2026-088774
Last updated: 2026-10-27

## Quick facts

- **Author:** Xiaojing Liu; Beibei Hua; Yang Xia; Huijie Huang; Areai Hakewati; Zeze Jin; Tumaris Halifu; Zaihua Xu ([Crossref](https://doi.org/10.32604/or.2026.088774))
- **Published:** 2026 ([Crossref](https://doi.org/10.32604/or.2026.088774))
- **Publisher:** Tech Science Press ([Crossref](https://doi.org/10.32604/or.2026.088774))
- **Journal:** Oncology Research ([Crossref](https://doi.org/10.32604/or.2026.088774))
- **DOI:** 10.32604/or.2026.088774 ([Crossref](https://doi.org/10.32604/or.2026.088774))

## Questions

**Who wrote Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer?**  
Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer was written by Xiaojing Liu, Beibei Hua, Yang Xia, Huijie Huang.

**When was Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer first published?**  
Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer was first published in 2026.

## Sources

- [Publisher record (DOI, via Crossref)](https://doi.org/10.32604/or.2026.088774)

## Licence and attribution

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.088774.

## Cite this page

"Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer". DigiNepal. Last updated 27 October 2026. https://diginpl.com/books/paper-or-2026-088774. Retrieved 14 November 2026.